skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 16.11d (Release date: 2016-11-28)
SearchBox Top
SearchBox Bottom
Glycooptimized Trastuzumab-GEX (Code C97917)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Glycooptimized Trastuzumab-GEX

Definition: A glycoengineered form of a monoclonal antibody directed against the human epidermal growth factor receptor-2 (HER2), with potential antineoplastic activity. Glycooptimized trastuzumab-GEX specifically binds to the extracellular domain of HER2, thereby inducing an antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-expressing tumor cells. This eventually results in apoptosis and growth inhibition of tumor cells. HER2, a member of the receptor tyrosine kinase EGFR superfamily, is overexpressed on the cell surfaces of various solid tumors. This agent has a specific glycosylation profile that may enhance its ADCC response against HER2-expressing tumor cells.

Label: Glycooptimized Trastuzumab-GEX

NCI Thesaurus Code: C97917 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL430400  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Ant-HER2 Monoclonal Antibody GT-Mab 7.3-GEX
Glycooptimized Trastuzumab-GEX
GT-Mab 7.3-GEX
TrasGEX

External Source Codes: 
PDQ Closed Trial Search ID 708211
PDQ Open Trial Search ID 708211 (check for NCI PDQ open clinical trial info)
NCI META CUI CL430400

Other Properties:
Name Value (qualifiers indented underneath)
code C97917
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C97917

Mainbox Bottom